1. Scrip
  2. >>Focus On Asia
  3. >>Japan

Takeda drops pioglitazone/metformin extended release combo in the EU

 
• By Ian Haydock

Takeda has withdrawn an EU marketing authorisation application for an extended release version of its oral antidiabetic product Competact, and has decided to discontinue the further development in the EU of this form of the fixed dose combination.

Takeda has withdrawn an EU marketing authorisation application for an extended release version of its oral antidiabetic product Competact, and has decided to discontinue the further development in the EU of this form of the fixed dose combination.

The once-daily formulation contains the thiazolidinedione derivative pioglitazone and metformin, a widely marketed biguanide, and was filed through the centralised...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Japan

Japan H1 Roundup: Pipeline Shifts Bring Mixed Results

 
• By Lisa Takagi

While Astellas and Daiichi Sankyo rang in double-digit growth, Eisai offset LOE impact with Leqembi’s performance. Takeda struggled with negative results but announced several growth initiatives.

Japanese Bioclusters Aim To Build Communities For Global Success

 
• By Lisa Takagi

Japan's leading bioclusters tell a session at BioJapan that building a tight-knit community will help better connect different players in the startup ecosystem and help ventures grow and expand internationally.

Industry Excellence Celebrated At Citeline Japan Awards

 
• By Ian Haydock

Excellence, innovation and deal-making across the Japanese biopharma sector were celebrated at the Citeline Japan Awards 2025, held in Tokyo on 21 October.

Viatris Looks To Expand Japan Presence With Aculys Acquisition

 
• By Lisa Takagi

Global generics-focused giant acquires Japanese venture with late-stage, two-asset CNS pipeline as it looks to build presence in Japan.

More from Focus On Asia

Aye Or Nay To Biosimilars For Sun Amid US Regulatory Easing?

 
• By Anju Ghangurde

Sun’s specialty gambit reaps gains with US sales surpassing generics for the first time in Q2 FY26, but will it finally enter the fray for biosimilars as the US moves to simplify regulatory requirements in the segment?

Aurobindo On Easier US Biosimilar Pathway, Zentiva Miss And Deal Strategy

 
• By Vibha Ravi

Do US FDA’s efforts at simplifying the biosimilar pathway create more competition and threaten Aurobindo Pharma's return on investments? Management speaks on this, biosimilar filing plans and deal strategy at the Q2 FY26 earnings call

Korean Biosimilars Giants Step Up Race To Become Innovators

 
• By Jung Won Shin

South Korea’s two biosimilars giants have laid out differing strategies to pursue innovative drug R&D, although both are positioning ADCs as a core focus.